Novel HF Drug Could Cut Mortality

ACC Conference Reporter

ESC 2015 | LONDON — The investigational non-steroidal mineralcorticoid receptor antagonist finerenone worked as well as eplerenone (Inspra) with a possible mortality advantage over the older drug in heart failure, the phase II ARTS-HF trial suggested. Read More >>>

Keywords: ESC Congress

< Back to Listings